VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma

Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, presents the subgroup analysis of the phase 2 SPRINT trial at the 20th Congress of the European Hematology Association (EHA). This results showed that lenalidomide, an immunomodulator, provided clinically significant improved activity irrespective of baseline demographics or disease characteristics when compared with investigator’s choice in patients with relapsed or refractory mantle cell lymphoma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter